Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company developing allogeneic CAR T (AlloCAR T) therapies for cancer and autoimmune disease. The ALLO news feed on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how its AlloCAR T pipeline progresses through development.
News about Allogene frequently highlights key milestones in its major programs. For oncology, updates include progress in the pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma, including trial design changes, site activations, and planned interim analyses focused on minimal residual disease (MRD) conversion. For autoimmune disease, releases cover the Phase 1 RESOLUTION trial of ALLO-329, a dual CD19/CD70 AlloCAR T candidate that incorporates the company’s Dagger® technology and is being studied across multiple rheumatologic indications.
Investors and observers can also find news on ALLO-316 in renal cell carcinoma through the TRAVERSE trial, including early clinical response data and discussions with regulators about potential pivotal development. Additional items include quarterly financial results, cash runway commentary, participation in investor and medical conferences, and 8-K summaries of material events such as changes in lymphodepletion strategy or intellectual property developments involving licensed TALEN-based gene-editing technology.
By following ALLO news, readers can track clinical catalysts, safety and biomarker findings, regulatory interactions, and corporate updates that may influence perceptions of Allogene’s AlloCAR T platform and its potential applications in hematologic malignancies, solid tumors, and autoimmune diseases.
Allogene Therapeutics (Nasdaq: ALLO) announced the addition of Dr. Jae Park, a leading expert in cell therapies, to its Scientific Advisory Board. Dr. Park, associated with Memorial Sloan Kettering Cancer Center, has extensive experience in CAR T therapies and is the principal investigator for multiple clinical trials. This appointment aims to enhance Allogene's research capabilities in developing allogeneic CAR T (AlloCAR T™) therapies for various cancers. The company seeks to leverage Dr. Park's expertise to advance its initiatives in treating blood cancers and solid tumors.
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company, announced its participation in two virtual investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 4:00 AM PT. The second is the BofA Global Research Global Healthcare Conference on September 16, 2021, at 10:25 AM PT. Webcasts will be available on their website following the events. Allogene specializes in allogeneic CAR T therapies aimed at making cell therapy more accessible to patients worldwide.
Allogene Therapeutics announced that the FDA granted orphan-drug designation (ODD) to its ALLO-715 therapy for multiple myeloma. This follows the previous Regenerative Medicine Advanced Therapy (RMAT) designation received in April 2021. The Phase 1 UNIVERSAL trial showed ALLO-715 can achieve clinical responses without the need for bridging therapy. The company plans to update on the trial by the end of 2021. With ODD, the therapy is entitled to various development incentives, including potential marketing exclusivity.
Allogene Therapeutics (ALLO) provided a significant update on its clinical pipeline and financials for Q2 2021. The company showcased promising data from its CD19 program, revealing a 75% overall response rate and 50% complete response rate in CAR T naïve patients with relapsed/refractory non-Hodgkin lymphoma. Financially, Allogene ended the quarter with $913 million in cash. Despite a net loss of $70.9 million, the company remains focused on pivotal trials for ALLO-501A and the development of new therapies, including ALLO-605, which received FDA Fast Track designation.
Allogene Therapeutics has appointed Elizabeth Barrett and Vicki Sato, Ph.D., to its Board of Directors, enhancing its leadership as it prepares for the industry's first pivotal trial of allogeneic CAR T therapy. Barrett, a veteran in oncology commercialization, previously led UroGen Pharma and Novartis Oncology, managing key CAR T launches. Dr. Sato brings her extensive experience from Vertex Pharmaceuticals and Biogen, focusing on unlocking the potential of cell therapy. Their expertise aims to bolster Allogene's efforts to deliver on-demand, off-the-shelf CAR T therapies.
Allogene Therapeutics (Nasdaq: ALLO) will announce its second quarter 2021 financial results on August 4, 2021, post-market close. The company, which specializes in developing allogeneic CAR T therapies for cancer, plans to host a live audio webcast at 2:00 PM PT/5:00 PM ET to discuss these results. The event aims to provide insights into the company's progress and future plans in the rapidly evolving field of biotechnology. Interested parties can access the webcast via the company's website.
Allogene Therapeutics, a clinical-stage biotechnology company based in South San Francisco, announced its participation in two virtual investor conferences. The events include William Blair's Biotech Focus Conference on July 14, 2021, at 5:55 AM PT and Canaccord Genuity's 41st Annual Growth Conference on August 11, 2021, at 7:00 AM PT. Webcasts will be available on their website under the Investors tab, with replays accessible for 30 days thereafter. Allogene focuses on developing allogeneic CAR T therapies for cancer, aiming for accessible and reliable cell therapy solutions.
Allogene Therapeutics has initiated the Phase 1 IGNITE Dose Escalation Trial for ALLO-605, a next-generation AlloCAR T therapy targeting BCMA for relapsed or refractory multiple myeloma. The FDA granted Fast Track designation to ALLO-605, highlighting its potential to address unmet medical needs. ALLO-605 employs TurboCAR technology, which enhances AlloCAR T cell function, potentially making it effective against solid tumors and hematologic malignancies. Allogene is pursuing an aggressive strategy with multiple candidates to benefit patients suffering from multiple myeloma.
Allogene Overland Biopharm has appointed Shuyuan Yao, Ph.D., as its Chief Executive Officer, effective immediately. Dr. Yao brings over 15 years of experience in cell and gene therapy, previously serving as Chief Scientific Officer at WuXi Advanced Therapies. His leadership is expected to drive the joint venture's mission to commercialize AlloCAR T™ therapies in China and Asia-Pacific markets. Allogene Overland focuses on the development of specific AlloCAR candidates targeting cancer biomarkers like BCMA and CD70, aiming to expand its global footprint in innovative therapies.
Allogene Therapeutics presented data at the 2021 ASCO Annual Meeting on its anti-CD19 AlloCAR T therapies, highlighting results from the ALLO-501 and ALLO-501A trials. The six-month complete response (CR) rate for CAR T naive large B-cell lymphoma (LBCL) patients was reported at 36%, with an overall response rate (ORR) of 75%. Safety profiles showed no dose-limiting toxicities or significant graft-vs-host disease. A potentially pivotal trial for ALLO-501A is anticipated by late 2021, indicating further developments in Allogene's clinical pipeline.